Welcome to Mediso

Please select your region:

North America
Europe
Rest of the World

Please select your language:

Go

Copper-67 Radioimmunotheranostics for Simultaneous Immunotherapy and Immuno-SPECT

2021.02.11.

Guiyang Hao et al., Nature.com Scientific Reports, 2021

Copper-67 Radioimmunotheranostics for Simultaneous Immunotherapy and Immuno-SPECT

Introduction

Copper-67 is useful from both therapeutic and diagnostic standpoints due to its medium energy beta particle, gamma emissions, and 2.6-day half-life. Moreover, since copper radioisotopes are chemically identical, the same radiopharmaceutical can be used for 64Cu PET imaging to pre-screen of patients and 67Cu based radionuclide therapy. For these reasons, the usage of 67Cu in radiotherapy has long been arisen. However until now, its widespread use has been limited by unreliable supplies, cost, and difficulty in obtaining therapeutic quantities. The recent breakthrough of copper-67 production provides an opportunity to reassess its use in radiotherapy.

Summary

In this work, Xiankai Sun and his co-workers have evaluated and demonstrated the practical use of 67Cu in radioimmunotherapy. To demonstrate the concept, human epidermal growth factor receptor 2 (HER2) antibody, pertuzumab, was labeled with 67Cu isotope. The radiolabeling efficiency was two-order of magnitude higher compared to literature reports. Mice bearing HER2+ xenografts showed 67Cu-dose dependent tumor-growth inhibition from 67Cu-labeled-Pertuzumab co-administered with trastuzumab. Moreover, authors visualized and measured [67Cu]Cu-NOTA-Pertuzumab uptake quantitatively by SPECT imaging.

Results from nanoScan® SPECT/CT

Thanks to technological advances of Mediso's SPECT/CT, researchers were able to perform quantitative data analysis.

Full article on nature.com

How can we help you?

Please contact us for technical information, products and services.

Get in touch